Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

842

Participants

Timeline

Start Date

March 7, 2011

Primary Completion Date

July 21, 2011

Study Completion Date

January 26, 2014

Conditions
InfluenzaInfluenza Vaccines
Interventions
BIOLOGICAL

Influenza A (H5N1) Virus monovalent vaccine

All subjects will receive 2 doses administered as an intramuscular (IM) injection.

BIOLOGICAL

Saline placebo

All subjects will receive 2 doses administered as an intramuscular (IM) injection.

Trial Locations (17)

40002

GSK Investigational Site, Khon Kaen

40004

GSK Investigational Site, Bardstown

44121

GSK Investigational Site, Cleveland

63141

GSK Investigational Site, St Louis

67114

GSK Investigational Site, Newton

68134

GSK Investigational Site, Omaha

70006

GSK Investigational Site, Metairie

76135

GSK Investigational Site, Fort Worth

76904

GSK Investigational Site, San Angelo

89014

GSK Investigational Site, Henderson

90723

GSK Investigational Site, Paramount

95816

GSK Investigational Site, Sacramento

V3K 3P4

GSK Investigational Site, Coquitlam

P3E 1H5

GSK Investigational Site, Greater Sudbury

L8L 5G8

GSK Investigational Site, Hamilton

J1H 1Z1

GSK Investigational Site, Sherbrooke

J1J 2G2

GSK Investigational Site, Sherbrooke

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01310413 - Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age | Biotech Hunter | Biotech Hunter